INmune Bio Inc. (INMB) Q4 2025 Earnings Call Transcript

INmune Bio held its Q4 2025 and year-end earnings call on March 30, 2026 at 4:30 PM EDT; presenters included CEO David Moss, CSO Mark Lowdell, Head of Neuroscience CJ Barnum, CFO Cory Ellspermann and IR head Daniel Carlson. The provided transcript excerpt contains participant introductions and the standard forward-looking statements disclaimer but includes no financial results, guidance, or material operational updates in the excerpt.

Analysis

INmune Bio sits in the classic small-cap, binary biotech bucket where clinical and funding cadence drive outsized moves; the market will likely treat any upcoming clinical readouts or regulatory interactions as 2x-3x re-rating events within a 3–12 month window. Second-order beneficiaries from any positive execution are not just the equity but CDMOs and GMP suppliers (companies like CTLT/CRL) that lock in multi-year manufacturing revenue; conversely, a negative outcome accelerates counterparty churn and forces early termination/renegotiation risk for those vendors.

Capital markets dynamics are the clearest near-term risk: if reported runway (implicit from this call) is <12 months, equity issuance is the highest-probability path to fund operations, which historically compresses existing holders by 30–60% on announcement; this flip-risk can occur on a weeks-to-months cadence and is reversible only with material clinical or partnering news. Clinical development itself is a multi-quarter story — efficacy/safety signals will phase into valuation jumps, but manufacturing scale-up and payer conversations extend the value realization to 12–36 months.

Consensus tends to underweight optionality around non-dilutive outcomes (partnerships, milestone licensing) because markets focus on cash runway; that asymmetry creates tradeable skew: downside is steep and fast, upside requires execution but could be multi-bagger if a strategic partner pays up. Manage exposure to volatility — implied vol often spikes ahead of catalysts, making straight long calls expensive; structured option trades and position sizing are the superior approach to capture upside while limiting dilution-driven drawdowns.

Key Decisions for Investors

• Event-driven protective long: Establish a small long position in INMB (1–2% NAV) sized to absorb a binary outcome, paired immediately with a protective 3–6 month put (cost = ≤25% of position) to cap downside to ~25–30% while leaving upside open for a 3–12 month clinical or partnering catalyst (target 2–4x upside).
• Volatility-efficient upside: Buy a 12–36 month LEAPS call spread (long-dated call spread) on INMB to capture multi-quarter upside while capping premium; allocate no more than 0.5–1% NAV, target asymmetry 3:1 upside vs premium paid if positive readout/partnering within 12–24 months.
• Short convexity / dilution hedge: Purchase 3–6 month OTM puts on INMB (cheap tail insurance) and/ or sell a small amount of near-term naked calls vs the long LEAPS to finance premium, anticipating a high probability (30–60%) of equity issuance if cash runway is under 12 months — trade size limit 0.5% NAV to avoid gamma risk.
• CDMO relative play: If seeking a cleaner exposure to favorable execution in the sector, overweight established CDMOs (example tickers: CTLT, CRL) on a 6–18 month horizon—they benefit from any small-cap program scale-ups without binary clinical risk. Allocate 1–2% NAV long CTLT/CRL as a diversification hedge to long INMB exposure.